Independent Medical Advisors — GI Oncologists Reviewing International Cases Daily
When you are facing pancreatic cancer, the question is not "who is the best doctor?" — it is "who is looking at my case with fresh eyes, and no financial incentive to send me anywhere?" Our independent advisors review de-identified cases from international patients — with one rule: if you do not need to travel, we will say so in writing.
Quick Answer — If You Have 30 Seconds
Our independent medical advisors are GI oncology specialists who review de-identified international cases — not to sell you a hospital, but to tell you whether international treatment is clinically justified at all.
Three things that define this review:
(1) Independence — reviewers are not employed by the receiving hospital, and we disclose our institutional revenue model.
(2) Honesty in writing — if your case is better managed locally, we will say so, in writing, before any travel planning begins.
(3) No medical decisions — we provide access intelligence, not treatment. Your oncologist remains the decision-maker.
The right question is not "Can I see a foreign doctor?" — it is "Would an independent review change anything for my case?" That is what this page helps you assess.
The Common Misconception — and What Actually Matters
Myth: "A second opinion from abroad will always give me more options."
Reality: Sometimes it does. Sometimes it confirms that your current plan is correct — and that confirmation has value too. The purpose of an independent review is not to find a reason to travel; it is to give you clarity. If the answer is "your local team is doing the right thing," that is a successful review.
The second myth: "Advisors who work with international hospitals will push me toward those hospitals."
Reality: Our reviewers are independent of the receiving institution. Our revenue comes from institutional partnerships — never from patient fees. And we publish this model. You can verify it. A review that only recommends travel is not a review — it is a sales pitch.
Key point: An honest advisor is measured not by how many patients they send abroad, but by how many they tell to stay home — when that is the clinically correct answer.
Who This Review Is For — and Who It Is Not For
An independent review is a tool. Like any tool, it works best when the job matches it.
This review is for you if…
- You have a pancreatic cancer diagnosis and want to know whether your current plan aligns with international guidelines
- Your doctor has said "nothing more can be done" — and you want a second set of eyes before accepting that
- You are considering a clinical trial abroad and need an independent assessment of eligibility and rationale
- You want a written, documented opinion you can discuss with your local oncologist
This review is not for you if…
- You want us to prescribe treatment or make clinical decisions — we do not
- You are looking for a specific hospital recommendation before understanding your options — see the China Trials page for trial verification first
- You have not yet had standard first-line treatment — international review is rarely the first step
- You are seeking emergency care — this is an educational review, not an emergency service
What Patients Say After an Independent Review
"I asked for a review because I was convinced I needed to go abroad. The advisor told me: 'Your current plan is correct. Travel would add risk, not benefit.' I was disappointed. Six months later, I understood it was the best advice I received. A review that tells you the truth is worth more than one that tells you what you want to hear."— 63-year-old patient, locally advanced PDAC, Tehran (identity withheld)
- Who actually reviews my case — and what are their credentials?
- Do the reviewers have any financial relationship with the hospitals they recommend?
- What records do I need to submit — and how are they protected?
- How long does the review take?
- What will the report actually contain — and what will it not contain?
- What if the review says "stay home" — will I still get a useful answer?
- Can my local oncologist speak directly with the reviewer?
Our Five Commitments to You
These are not marketing statements. They are the operational rules that govern every review we conduct.
Independence in writing
Our reviewers are not employed by the receiving hospital. If a reviewer has a conflict of interest with a specific institution, they are excluded from that case. We publish our institutional revenue model on our Financial Transparency page — so you can verify how we are funded, and what we are not funded by.
Honesty before travel
If your case is better managed by your local team, we will say so in writing — before any travel planning begins. A review that always recommends travel is not a review. We will tell you when staying home is the clinically correct answer.
No medical decisions
We provide access intelligence, not treatment. The review summarizes the evidence, identifies options, and flags questions — but the final decision remains with you and your treating oncologist. We do not prescribe, diagnose, or make clinical recommendations.
Documented, shareable output
You receive a written report — not a phone call that disappears. The report is designed to be shared with your local oncologist, so the review becomes part of your clinical conversation — not a separate, competing opinion.
Zero patient fees
Patients never pay us. Our coordination is funded by institutional partnerships — not by patients. This is not a discount; it is the structural reason our advice can remain independent. If a service charges you for a “review,” ask who is paying for the recommendation.
How the Independent Review Works — Step by Step
No mystery. This is the exact process, from your first message to the written report.
You share your case — de-identified
You send your diagnosis, treatment history, and key reports (pathology, imaging summaries, molecular results if available). No medical records are stored on our servers. The review is based on a structured summary, not raw files.
A GI oncology specialist reviews your case
Your case is assigned to a reviewer with experience in pancreatic cancer. The reviewer assesses: whether the current plan aligns with international guidelines, whether clinical trial options exist, and whether international treatment would meaningfully change the trajectory.
You receive a written report
The report includes: a summary of the evidence reviewed, the reviewer's assessment, flagged questions for your local oncologist, and — if relevant — a list of potential access pathways (trials, centers) with the caveat that eligibility must be verified independently.
You discuss the report with your local oncologist
The report is designed to support your local clinical relationship — not replace it. If your oncologist has questions, we can facilitate a direct conversation with the reviewer. The goal is a better-informed local decision, not a competing one.
If travel is justified, we explain the next steps
Only after the review — and only if the clinical rationale supports it — do we discuss access pathways. The review comes first. Travel comes second. If the answer is "stay home," we say so, and the process ends there.
How to Tell a Useful Review from a Marketing Pitch
Not every "second opinion" service is independent. Here is how to distinguish them — including how to evaluate us.
| Question to ask | Useful review | Marketing pitch |
|---|---|---|
| Who pays the reviewer? | Disclosed openly | Hidden or vague |
| Will they say "stay home"? | Yes — in writing | Rarely or never |
| Do they prescribe treatment? | No — they inform | Yes — "we recommend..." |
| Is the output written and shareable? | Yes — documented | Phone call only |
| Do they disclose conflicts of interest? | Yes — explicitly | No disclosure |
| Do they pressure you to decide? | No — you set the pace | Urgency tactics |
| Can your local oncologist speak to the reviewer? | Yes — encouraged | Discouraged |
Frequently Asked Questions
Who are the independent medical advisors — and what are their credentials?
Our reviewers are GI oncology specialists with experience in pancreatic cancer. We do not publish individual advisor names or credentials on this page — because the review process is institutional, not personal, and because individual advisor availability changes. What we publish is the process: independence rules, conflict-of-interest policy, and the structure of the written report. If you need to know who reviewed your specific case, we can share that with you directly.
Do the reviewers have financial relationships with hospitals?
Reviewers are independent of the receiving institution. If a reviewer has a conflict of interest with a specific hospital, they are excluded from cases involving that hospital. CancerCareE is funded by institutional partnerships — not by patient fees. This model is published on our Financial Transparency page. We encourage you to verify it before requesting a review.
What records do I need to submit — and how are they protected?
For a meaningful review, you need: pathology report, treatment history, key imaging summaries, and molecular test results (if available). We do not store raw medical records. The review is based on a structured, de-identified summary that you or your local team prepares. This is a privacy-first design, not an afterthought.
How long does the review take?
Most reviews are completed within 48–72 hours of receiving a complete case summary. Complex cases may take longer. If a case requires additional information (e.g., missing molecular results), we will tell you what is needed before the clock starts.
What if the review says "stay home"?
That is a valid and valuable outcome. A review that confirms your local plan is working is not a failed review — it is a successful one. You will receive a written report explaining the reasoning, so you can discuss it with your local oncologist with confidence. We do not consider "stay home" a lost case; we consider it a correct answer.
Can my local oncologist speak directly with the reviewer?
Yes — and we encourage it. The purpose of the review is to support your local clinical relationship, not to create a competing opinion. If your oncologist has questions about the report, we can facilitate a direct conversation with the reviewer. This is how the review becomes part of your care, rather than separate from it.
Is this page a directory of doctors I can book directly?
No. This is not a booking page. It explains how independent review works — and what you can expect from it. If the review identifies a potential access pathway (trial, center), that is a separate conversation that happens after the review, not before. For trial verification specifically, see the China Trials page.
If You Are Considering an Independent Review — But Are Not Sure It Is Right for You
We are not here to convince you to request a review. If you have questions about the process — who reviews, how it works, what the report contains, or whether your case is a good fit — you can ask us directly. And if the answer is "your local team is doing the right thing," we will say so.
We reply within 48 hours. If the review is not right for your case, we will say so honestly.
Continue Your Pancreatic Cancer Research
This page explains the review process. If you want to go deeper into the clinical questions first, these focused pages are the natural next step.
KRAS Mutations & Targeted Therapy
What each KRAS variant means — approved drugs vs trials, and a 10-question NGS report checklist.
Read the KRAS guide 🧪Patient-Derived Organoid Testing
What organoid testing can and cannot tell you — and 12 questions to ask the lab before you commit.
Learn about organoids 🇨🇳Clinical Trials in China
How to identify relevant trials, review eligibility, and verify whether international patients can participate.
Explore China trialsReferences
- CancerCareE — Financial Transparency and Editorial Policy. cancercaree.com/financial-transparency/
- National Comprehensive Cancer Network (NCCN) — Clinical Practice Guidelines in Oncology: Pancreatic Adenocarcinoma. nccn.org
- American Society of Clinical Oncology (ASCO) — Pancreatic Cancer treatment guidelines. asco.org
- National Organization for Rare Disorders (NORD) — Tip Sheet for Medical Advisory Board Recruitment and Management. rarediseases.org
- PubMed — Biomedical literature database. pubmed.ncbi.nlm.nih.gov